OPENING CEREMONY AND KEYNOTE LECTURE

• Comparing and Contrasting COVID-19 Control with HPV Control and Elimination

Barney Graham, USA

PLENARY SESSION 1

• One-dose HPV vaccination overview and a focus on the KENSHE data

Ruanne Barnabas, USA

• New prophylactic HPV vaccines

Richard Roden, USA

• Therapeutic vaccines in particular with clinical outcomes such as CIN 3

Mayumi Nakagawa, USA

PLENARY SESSION 2

• Lessons learned from other disease control programs such as HIV

Helen Rees, South Africa

• What can we learn from the hepatitis B model in elimination of HPV-related diseases?

 Mark Kane, USA

• Anal cancer control approaches

Joel Palefsky, USA

16:40-18:00

PLENARY SESSION 3

• Mastomys Coucha: a unique animal model for papillomavirus-induced skin carcinogenesis

Frank Rosl, Germany

• Pros and cons of Beta HPVs as causative agents in skin cancer

Denise Galloway, USA

*Special Tribute to Massimo Tommasino on his work on Epidemiology and Biology of Beta Human Papillomavirus Types

PLENARY SESSION 4

• Covid-19 effect on cervical screening

Mona Saraiya, USA

• Re-invigorating efforts towards cervical cancer elimination: mitigating the impact of Covid-19

Karen Canfell, Australia

• What will it take (and how to) achieve cervical cancer elimination goal by 2030 with a perspective for low and middle income countries?

Yin Ling Woo, Malaysia

16:00-17:15

CLOSING CEREMONY AND KEYNOTE LECTURE

• The future is now

 Douglas Lowy, USA